Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2010
03/31/2010CN101683337A Application of corynantheine in preparing medicament for treating heart disease induced by myocardial damage
03/31/2010CN101683336A Nitrendipine sustained-release preparation and preparation method thereof
03/31/2010CN101683334A (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
03/31/2010CN101683332A high purity scutellarin salt bulk drug and preparation method thereof
03/31/2010CN101683329A Application of histone deacetylase inhibitor in treating atherosclerosis
03/31/2010CN101683320A Olprinone hydrochloric parenteral solution and method for preparing same
03/31/2010CN101683159A Hypotensive food
03/31/2010CN100596276C Slow-released vincamine capsule and its preparation process
03/30/2010US7687664 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
03/30/2010US7687643 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
03/30/2010US7687637 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors
03/30/2010US7687606 Fully human monoclonal antibodies that inhibit neovascularization of solid tumors; assaying for MCP-1; cancer diagnosis; may be conjugated to a chemotherapeutic agent such as taxol, doxorubicin, cis-platinum, and 5-fluorouracil.
03/30/2010US7687546 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease
03/30/2010US7687536 Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
03/30/2010US7687514 Benzimidazole derivatives
03/30/2010US7687510 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
03/30/2010US7687505 Use of modified pyrimidine compounds to promote stem cell migration and proliferation
03/30/2010US7687503 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders
03/30/2010US7687502 Substituted quinazoline or pyridopyrimidine derivative
03/30/2010US7687494 Substituted spirobenzazepines
03/30/2010US7687489 Agent for treatment of cerebral ischemic diseases
03/30/2010US7687485 Formulation for menopausal women
03/30/2010US7687480 Phosphonate compounds
03/30/2010US7687479 Characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin
03/30/2010US7687059 Systems and methods for treating patients with processed lipoaspirate cells
03/30/2010US7687056 containing granulocyte colony-stimulating factor; diabetic nephropathy
03/30/2010CA2537420C Bd crystalline form of ivabradine chlorhydrate, process for the preparation thereof and pharmaceutical compounds containing it
03/30/2010CA2472237C Multi-stage oral drug controlled-release system
03/30/2010CA2457444C 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
03/30/2010CA2442245C 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
03/30/2010CA2428642C Methods for large scale production of recombinant dna-derived tpa or k2s molecules
03/30/2010CA2423631C 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
03/30/2010CA2420894C Thienopyrimidines
03/30/2010CA2362277C Spontaneously dispersible n-benzoyl staurosporine compositions
03/30/2010CA2306429C Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5t h1a receptors
03/30/2010CA2297023C Use of lactobacillus for reduction of the fibrinogen level in blood
03/30/2010CA2229479C Method of promoting angiogenesis
03/30/2010CA2176183C 3-substituted oxindole derivatives as potassium channel modulators
03/30/2010CA2155004C Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
03/25/2010WO2010033560A2 Sur1 inhibitors for therapy
03/25/2010WO2010032007A1 Use of ctgf as a cardioprotectant
03/25/2010WO2010031852A1 Novel estrogen receptor ligands
03/25/2010WO2010031248A1 Thiazolium salt compound and the use of treating the protein aging disease
03/25/2010WO2010004283A3 Sulfonylurea receptor and means for treating ischaemia
03/25/2010WO2010002450A3 Micelles for delivery of nitric oxide
03/25/2010WO2010002231A3 Composition for preventing or treating hyperproliferative vascular disease containing extracts from thorns of gleditsia sinensis
03/25/2010WO2009154741A8 Thiophene or thiazole derivatives and their use as pi3k inhibitors
03/25/2010WO2009127974A3 Pharmaceutical formulation for treating cardiovascular disease
03/25/2010WO2009117677A3 Controlling intracellular calcium levels associated with an ischemic event with o-desulfated heparin
03/25/2010US20100076256 Cardiac disease treatment and device
03/25/2010US20100076188 2-((4,6-dimethoxy)pyrimidin-2-yl-),3-(methoxy-), 3,3-(diphenyl)propionic acid; antihypotensive agents; pulmonary hypertension, mycocardial necrosis; renal failure; brain disorders; antispasmodic agents; antiischemic agents; coagulants; asthma; atherosclerosis; restenosis; Raynaud's syndrome
03/25/2010US20100076083 Treprostinil administration using a metered dose inhaler
03/25/2010US20100076063 Genetic modification of targeted regions of the cardiac conduction system
03/25/2010US20100076047 Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt
03/25/2010US20100076027 Indazole or 4,5,6,7-tetrahydro-indazole derivatives
03/25/2010US20100076021 Organic Compounds
03/25/2010US20100076010 Alpha 1a-adrenoceptor antagonists
03/25/2010US20100076002 Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions
03/25/2010US20100075974 Heterocyclic gpr40 modulators
03/25/2010US20100075964 Imidazole based lxr modulators
03/25/2010US20100075941 Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
03/25/2010US20100075937 Patient populations and treatment methods
03/25/2010US20100075935 Xanthine modulators of adenosine a1 receptor
03/25/2010US20100075932 Novel salicylic anilides
03/25/2010US20100075926 Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
03/25/2010US20100075923 Method of enhancing tgf-beta signalling
03/25/2010US20100075922 Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof
03/25/2010US20100075907 Neuromedin u receptor agonists and uses thereof
03/25/2010US20100075900 Use of Nutritional Compositions for Preventing Disorders
03/25/2010US20100075898 N-terminal vdac variants and uses thereof
03/25/2010US20100075894 Reducing er stress in the treatment of obesity and diabetes
03/25/2010US20100074958 Methods and compositions for targeting fenestrated vasculature
03/25/2010US20100074953 Methods for intiating in situ formation of hydrogels
03/25/2010US20100074952 Tasted masked veterinary solid compositions
03/25/2010US20100074951 Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
03/25/2010US20100074934 Medical implants with a combination of compounds
03/25/2010US20100074900 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
03/25/2010US20100074899 Methods for treating conditions associated with masp-2 dependent complement activation
03/25/2010US20100074887 Methods for Treating and Diagnosing Fibrotic and Fibroproliferative Diseases
03/25/2010CA2737738A1 Heterocyclic carboxamide compounds
03/25/2010CA2737448A1 Use of ctgf as a cardioprotectant
03/24/2010EP2166095A2 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes in endothelial cells
03/24/2010EP2166087A2 FAD4, FAD5, FAD5-2 et FAD6, fatty acid desaturase family members and uses thereof
03/24/2010EP2166020A1 Peptide having hypotensive activity
03/24/2010EP2166010A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2166009A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
03/24/2010EP2166008A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2165999A1 Formoterol tartrate process and polymorph
03/24/2010EP2165605A1 Use of a ribonuclease of the T2 family having actin-binding activity for inhibiting and/or reversing proliferation
03/24/2010EP2164500A1 The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
03/24/2010EP2164497A1 A drug delivery system for the prevention of cerebral vasospasm
03/24/2010EP2164484A1 Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension
03/24/2010EP2046791B1 Urea derivatives of tropane, their preparation and their therapeutic application
03/24/2010EP1389110B1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/24/2010EP1328511B1 Substituted (e)-styryl benzylsulfones for treating proliferative disorders
03/24/2010EP1112005B2 Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid
03/24/2010EP1075496B1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
03/24/2010EP1003370B1 Method of enhancing magnesium absorption and prevention of atherosclerosis
03/24/2010CN201426435Y Pine needle health-care shoe pad
03/24/2010CN101679988A Fusion proteins binding to growth factors
1 ... 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 ... 1595